TLRY

Tilray Inc
NASDAQHEALTHCAREDRUG MANUFACTURERS - SPECIALTY & GENERIC

Key Statistics

Market Cap
$619.11M
P/E Ratio
EPS
$-1.09
Beta
1.92
52W High
$23.20
52W Low
$3.67
50-Day MA
$4.46
200-Day MA
$6.63
Dividend Yield
Profit Margin
-13.30%
Forward P/E
1000.00
PEG Ratio

About Tilray Inc

Tilray Inc. is dedicated to the research, cultivation, production and distribution of medicinal cannabis and cannabinoids. The company is headquartered in Leamington, Canada.

Official WebsiteUSAFY End: May

Fundamentals

Revenue (TTM)$915.45M
Gross Profit (TTM)$262.59M
EBITDA$15.00M
Operating Margin-52.70%
Return on Equity-6.82%
Return on Assets-1.49%
Revenue/Share (TTM)$8.19
Book Value$3.02
Price-to-Book0.39
Price-to-Sales (TTM)0.68
EV/Revenue0.863
EV/EBITDA83.61
Quarterly Earnings Growth (YoY)0.00%
Quarterly Revenue Growth (YoY)-7.80%
Shares Outstanding$137.58M
Float$437.31M
% Insiders1.67%
% Institutions10.91%

Historical Volatility

HV 10-Day
34.82%
HV 20-Day
54.92%
HV 30-Day
55.79%
HV 60-Day
47.18%
HV Rank

Volatility is currently contracting

Analyst Ratings

Consensus ($7.84 target)
1
Buy
1
Hold

Latest News

3 Top Marijuana Stocks to Watch in September 2026

The cannabis industry is entering September, and investors are once again searching for opportunities across the sector. After years of volatility, several marijuana companies are showing signs of stronger financial performance. Revenue is improving for some operators. Meanwhile, others are cutting costs, strengthening margins, and expanding internationally. That combination could put marijuana stocks back on investors' radar. However, this is no longer simply a story about rapid expansion. Investors are becoming more selective about which cannabis companies deserve their attention. Today, profitability matters. Cash flow matters. Additionally, investors want companies with strong brands and opportunities beyond their existing markets. International cannabis growth has become particularly important. Europe continues expanding its medical cannabis industry. As a result, Canadian producers are positioning themselves to capture growing international demand. Meanwhile, the United States remains an important potential catalyst. Changes to federal cannabis regulations could eventually reshape the industry's investment landscape.

MarijuanaStocks9/1/2026Positive
Tilray Posted Record Fiscal 2026 Revenue -- Why Isn't the Stock Rallying?

Tilray's management may have touted "record" numbers for the company's recently completed fiscal year, but a closer look suggests mixed results at best. Dilution concerns and a limited exposure to potential U.S. regulatory changes may also explain why investors aren't lining up to bid up the stock.

The Motley Fool8/23/2026Negative
Tilray Strengthens Global Medical Cannabis Leadership with Major Production Increase to Meet International Demand

Expanded cultivation in Quebec and Portugal strengthens Tilray's global cannabis platform, increasing total annual production capacity to approximately 275 metric tonnes to support accelerating international medical cannabis demand. Expanded cultivation in Quebec and Portugal strengthens Tilray's global cannabis platform, increasing total annual production capacity to approximately 275 metric tonnes to support accelerating international medical cannabis demand.

GlobeNewsWire8/20/2026Neutral

Turn research into an automated options-selling system

Tiblio connects your broker and runs your put-and-call-writing strategy for you — on TLRY and any ticker you trade — then tracks every position and per-strategy win rate.

See how it works

More HEALTHCARE Stocks

Data last updated: 9/7/2026